Page 14 - Read Online

these problems, pharmaceutical formulators started to divert 7. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y,
their effort from nanoDDS to simple bioconjugate techniques Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report:
to directly attach old problematic active pharmaceutical primary brain and central nervous system tumors diagnosed in the United
agents such as stimuli-sensitive moieties, targeting agents, 8. States in 2006-2010. Neuro Oncol 2013;15 Suppl 2:ii1-56.
Molnár Pt. Classification of primary brain tumors: molecular aspects,
pharmacokinetics-modifying mediators, diagnostic agents, cell- management of CNS tumors. InTech;2011.
penetrating peptides, protective PEGylation layer, or antibodies. 9. Chandana SR, Movva S, Arora M, Singh T. Primary brain tumors in
Active pharmaceutical ingredients can be directly conjugated adults. Am Fam Physician 2008;77:1423-30.
to antibodies against specific cell-type markers to create a 10. Parrish KE, Sarkaria JN, Elmquist WF. Improving drug delivery to
hybrid smart molecule that is able to direct the active molecule primary and metastatic brain tumors: Strategies to overcome the blood-
to the disease tissue specifically. Consequently, many patents brain barrier. Clin Pharmacol Ther 2015;97:336-46.
currently focus on simple bioconjugate structuresthat are easily 11. Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and
treatment. Pharmacol Ther 2015;152:63-82.
synthesized with high yield, reduced cost, and high stability of 12. Armstrong TS. Head’s up on the treatment of malignant glioma patients.
the final formulation. This could provide a practical direction for Oncol Nurs Forum 2009;36:E232-40.
the development of novel management tools and therapeutics 13. Wen PY, Kesari S. Malignant Gliomas in Adults. N Engl J Med
for brain cancer for researchers worldwide, paving the road 2008;359:492-507.
to affordable, scalable, stable, efficient, and safe management 14. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept
strategies. to clinical diagnosis. Neuro Oncol 1999;1:44-51.
15. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview:
structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13.
All such techniques and technologies were illustrated in the 16. Cook LJ, Freedman J. Brain Tumors. New York: The Rosen Publishing
recent patents analyses discussing brain drug delivery during Group; 2012.
2010 to 2015. Despite such efforts, the development of brain 17. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA,
drug delivery carrier system is still costly and troublesome in Scherrmann JM, De Waziers I, Decleves X. Expression and transcriptional
its transformation from bench to bedside. Such systems require regulation of ABC transporters and cytochromes P450 in hCMEC/D3
huge effort in their in vivo, in vitro testing and clinical trials. Most human cerebral microvascular endothelial cells. Biochem Pharmacol
2009;77:897-909.
of the research funding in academia for brain delivery research 18. Abbott NJ, Friedman A. Overview and introduction: the blood-brain
comes from investing companies. Most of the companies barrier in health and disease. Epilepsia 2012;53:1-6.
investing in this field are small startups such as to-BBB and 19. van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger
BiOasis Therapeutics. If such industrial startups fail to develop T, de Vries HE. Overcoming the blood-brain tumor barrier for effective
a promising moiety or carrier for brain drug delivery, their glioblastoma treatment. Drug Resist Updat 2015;19:1-12.
existence is usually jeopardized. [154,155] An integrated ”bench- 20. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in
to-clinic” approach, realized through a structural collaboration health and disease. Pharmacol Rev 2005;57:173-85.
between industry and academia, would strongly promote the 21. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters,
treatment, and Trojan horses. Clin Cancer Res 2007;13:1663-74.
development of brain tumor-targeted nanomedicines towards 22. Barthomeuf C, Chollet P, Bayet-Robert M. Curcuminoids in Combination
effective and safe clinical application. [156] Docetaxel for the Treatment of Cancer and Tumour Metastasis. In: Institut
National De La Sante Et De La Recherche Medicale (Inserm); 2014.
Financial support and sponsorship (ISBN No. US20140128337 A1)
Nil. 23. Loscher W, Potschka H. Blood-brain barrier active efflux transporters:
ATP-binding cassette gene family. NeuroRx 2005;2:86-98.
Conflicts of interest 24. Ghosh C, Gonzalez-Martinez J, Hossain M, Cucullo L, Fazio V, Janigro
D, Marchi N. Pattern of P450 expression at the human blood-brain barrier:
There are no conflicts of interest. Roles of epileptic condition and laminar flow. Epilepsia 2010;51:1408-17.
25. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G. Drug metabolizing
REFERENCE enzymes in the brain and cerebral microvessels. Brain Res Brain Res Rev
1991;16:65-82.
1. Jex HS. The Edwin Smith Surgical Papyrus: first milestone in the march of 26. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ.
medicine. Merck Rep 1951;60:20-2. Advanced MRI and PET imaging for assessment of treatment response in
2. Sanchez GM, Meltzer ES. The Edwin Smith Papyrus: Updated translation of patients with gliomas. Lancet Neurol2010;9:906-20.
the trauma treatise and modern medical commentaries: Lockwood Press;2012. 27. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Ther
3. Brayn CP, Smith GE. The Papyrus Ebers, translated from the german Deliv 2013;4:10.4155/tde.13.38.
version. Letchworth, Herts. The Guardian City Press LTD;1930. 28. Madsen SJ, Hirschberg H. Site-specific opening of the blood-brain barrier.
4. Papavramidou N, Papavramidis T, Demetriou T. Ancient Greek and J Biophotonics 2010;3:356-67.
Greco-Roman methods in modern surgical treatment of cancer. Ann Surg 29. Kazantsev AG, Outeiro TF. Drug discovery for CNS disorders: from
Oncol 2010;17:665-7. bench to bedside. CNS Neurol Disord Drug Targets 2010;9:668.
5. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin 30. Gabathuler R. Approaches to transport therapeutic drugs across the blood-
DM, Forman D, Bray F. Globocan 2012, Cancer Incidence and Mortality brain barrier to treat brain diseases. Neurobiol Dis 2010;37:48-57.
Worldwide: IARC. In: internet N, editor. Cancer Fact Sheets. Lyon, 31. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab
France: International Agency for Research on Cancer; 2013. 1997;17:713-31.
6. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical 32. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD,
report: primary brain and central nervous system tumors diagnosed in the Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM,
United States in 2005-2009. Neuro Oncol 2012;14 Suppl 5:v1-49. Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ March 15, 2016 ¦ 119